OptiNose files for $100M IPO; GSK wins three-in-one COPD OK
⇨ Yardley, PA-based OptiNose is joining the growing line for Nasdaq, filing for a $100 million IPO, according to the S-1. The filing came right on the heels of an OK for XHANCE — previously referred to by the development name OPN-375 — for the treatment of nasal polyps.
⇨ GSK got some good news today, winning FDA approval of the first three-in-one once-daily therapy for COPD. The move comes after the EMA endorsed the inhaler last week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.